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Background: IL-1β has been shown to play a pivotal role in autoimmunity. Cysteinyl aspartate-specific proteinase-1
(caspase-1) inhibitor may be an important drug target for autoimmune diseases. However, the effects of caspase-1
inhibitor on myasthenia gravis (MG) remain undefined.
Methods: To investigate the effects of caspase-1 inhibitor on experimental autoimmune myasthenia gravis (EAMG),
an animal model of MG, caspase-1 inhibitor was administered to Lewis rats immunized with region 97–116 of the
rat AChR α subunit (R97-116 peptide) in complete Freund’s adjuvant. The immunophenotypical characterization by
flow cytometry and the levels of autoantibody by ELISA were carried out to evaluate the neuroprotective effect of
caspase-1 inhibitor.
Results: We found that caspase-1 inhibitor improved EAMG clinical symptom, which was associated with decreased
IL-17 production by CD4+ T cells and γδ T cells, lower affinity of anti-R97-116 peptide IgG. Caspase-1 inhibitor decreased
expression of CD80, CD86, and MHC class II on DCs, as well as intracellular IL-1β production from DCs. In addition,
caspase-1 inhibitor treatment inhibited R97-116 peptide-specific cell proliferation and decreased follicular helper T cells
relating to EAMG development.
Conclusions: Our results suggest that caspase-1 inhibitor ameliorates experimental autoimmune myasthenia gravis by
innate DC IL-1-IL-17 pathway and provides new evidence that caspase-1 is an important drug target in the treatment
of MG and other autoimmune diseases.
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myasthenia gravisBackground
Myasthenia gravis (MG) is an antibody-mediated, T cell-
dependent, complements involved autoimmune disease
[1, 2], characterized by loss of acetylcholine receptor
(AChR) on the postsynaptic membrane of neuromuscu-
lar junction and resulted in impaired neuromuscular
transmission and muscle weakness. Experimental auto-
immune myasthenia gravis (EAMG) can be induced in
Lewis rats by immunization with torpedo acetylcholine
receptor (TAChR) or a synthetic peptide corresponding* Correspondence: ruisheng_duan@yahoo.com
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(http://creativecommons.org/publicdomain/zeroto region 97–116 of the rat AChR α subunit (R97-116
peptide), which is a reliable model for human MG and is
suitable for investigating the development of novel
therapeutic strategies. CD4+ T helper cells involving
Th1, Th2, Th17, and T regulatory (Treg) cells have been
shown to play a crucial role in the pathogenesis of
EAMG since they assist autoreactive B cells to produce
anti-AChR antibodies.
IL-1β is a highly active pro-inflammatory cytokine pro-
duced by limited cells, such as dendritic cells, tissue
macrophages, and blood monocytes, depending on the
activation of caspase-1 [3]. Both pro-IL-1β and pro-
IL-18 as inactive precursors are cleaved by the active
caspase-1 into functional forms [4, 5]. Caspase-1 itself isicle distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in
operly credited. The Creative Commons Public Domain Dedication waiver
/1.0/) applies to the data made available in this article, unless otherwise stated.
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tive caspase-1 in the inflammasome [6].
IL-1β and IL-18 can induce the secretion of IL-17
from many cells of the innate immune system, including
γδ T cells and invariant natural killer T (iNKT) cells [7,
8]. Mature IL-1β binds first to the type 1 IL-1 receptor
(IL-1RI) on their cell surface and forms the receptor
complex with IL-1R accessory protein (IL-1RAcP) [9,
10]. The Toll-IL-1 receptor (TIR) domains of receptor
complex recruits the adaptor molecule MyD88, conse-
quently, NF-κB is phosphorylated. Phosphorylated NF-κB
translocates to the nucleus and induces the transcription
of pro-inflammatory cytokines [11]. IL-1-targeted drugs,
such as the IL-1 receptor antagonist anakinra and the
neutralizing monoclonal anti-IL-1β antibody canakinu-
mab, result in a rapid and sustained remission in inflam-
matory diseases [12]. Daily injections of IL-1 receptor
antagonist (IL-1ra) decreased the severity of clinical
EAMG in C57BL/6 mice with suppressed serum IFN-γ,
TNF-α, IL-1β, C3, and anti-AChR IgG1 [13].
It has recently been reported that caspase-1 is critical
for the induction of IL-17 production in innate immune
cells. The role of caspase-1 in EAE pathogenesis has
been demonstrated, and caspase-1 protein and activity
were upregulated during the inflammatory stages of the
disease. Caspase-1−/− mice were less susceptible to EAE,
and this was associated with impaired Th1 cell develop-
ment and reduced perivascular infiltrates in the CNS.
Inhibition of caspase-1 in vivo suppressed the develop-
ment of Th17 cells and the induction of EAE, and this
was reversed by administration of IL-1β or IL-18, more
dramatic with IL-1β [14].
In addition, some studies have confirmed that the acti-
vated caspase-1 could lead to an upregulation of MHC
class II, CD80, and CD86 on DC through the secretion of
IL-1β [15]. We addressed the hypothesis that caspase-1
may be an important drug target for autoimmune diseases.
In this study, we examined the role of caspase-1 in-
hibitor on innate DC IL-1-IL-17 pathway, provided a po-
tential therapeutic strategy to MG.
Methods
Animals and reagents
Female Lewis rats weighing 160–180 g (age from 6 to 8
weeks) were purchased from Vital River Laboratories
(Beijing, China) and kept at the local animal house
under specific pathogen-free conditions, with standard
rat chow and water ad libitum. All experiments were
approved by the guidelines of the Animal Ethics Com-
mittee of Shandong University. Minimum number of an-
imals was used to result in meaningful interpretation of
data, and animal pain and discomfort was kept to a
minimum level. The caspase-1 inhibitor Ac-YVAD-cmk
was purchased from Cayman Chemical (Ann Arbor, Ml,USA), and Recombinant Rat IL-1β was purchased from
Peprotech (Rocky Hill, NJ, USA). R97-116 peptide
(DGDFAIVKFTKVLLDYTGHI) was synthesized by CL
BIO-SCIENTIFIC CO. LTD. (Xian, China).
Elicitation of EAMG
Rats were injected subcutaneous into both hind foot
pads with 200-μl inoculum containing 50 μg R97-116
peptide, 1 mg. Mycobacterium tuberculosis (strain
H37RA; Difco, Detroit, MI, USA) in incomplete Freund’s
adjuvant (Sigma-Aldrich, St. Louis, MO, USA) on day 0
and were boosted with the same dose along the back on
day 11 after the first immunization.
Rats were randomly divided into respective groups (6
rats/group). From day 13 after the first immunization,
rats in the Ac-YVAD-cmk treatment group (at doses of
100 μg/rat in a volume of 0.4-ml PBS) were administered
intraperitoneally (i.p.) every second day. Rats in the Ac-
YVAD-cmk with IL-1β group were injected i.p. with Ac-
YVAD-cmk (at doses of 100 μg/rat in a volume of 0.4 ml
PBS) from day 13 after the first immunization and IL-1β
(at doses of 0.4 μg/rat in a volume of 0.4-ml PBS) from
day 14 after the first immunization every second day.
EAMG rats were administered with vehicle (PBS) at the
same time points.
Clinical evaluation
Clinical scoring was based on the presence of tremor,
hunched posture, muscle strength, and fatigability in a
double-blind fashion. Fatigability was assessed after exer-
cise (repetitive paw grips on the cage grid) for 30 s. Dis-
ease severity was graded as follows [16]: 0, normal
strength and no abnormalities; 1, mildly decreased activity
and weak grip or cry, more evident at the end of exercise;
2, clinical signs present before exercise (tremor, head
down, hunched posture, and weak grip); 3, severe clinical
signs present before exercise, no grip moribund; 4, dead.
Rats with intermediate signs were assigned grades of 0.5,
1.5, 2.5, or 3.5, respectively. Results were expressed as the
mean score for each group at each time point.
DC preparation
Spleen mononuclear cell (MNC) suspensions from Lewis
rats were prepared by grinding spleen through a cell
strainer (Becton Dickenson, Franklin Lakes, NJ, USA) in
medium, then depleted of erythrocytes with osmotic lysis.
Cells were incubated in 25 mm2 Falcon culture flasks
(Becton Dickinson). After 1 h 40 min, non-adherent cells
were gently removed. New RPMI 1640 (containing 2.05
mM glutamine, HyClone, Beijing, China) medium contain-
ing 1 % (v/v) penicillin-streptomycin (Shandong Lukang
Cisen, Jining, China) and 10 % fetal bovine serum (FBS;
Gibco, Grand Land, NY, USA) were added to the flasks.
After 18 h of incubation, non-adherent DC were collected.
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were cultured in RPMI 1640 medium supplemented with
1 % (v/v) penicillin-streptomycin (Shandong Lukang Cisen),
10 % (v/v) fetal bovine serum (Gibco), 10 ng/ml of
GM–CSF (Peprotech) and 10 ng/ml IL-4 (Peprotech).
After a total culture time of 8 days, non-adherent DC
were collected. The DC-enriched population contained
75–85 % DC by staining with OX62 mAb, which specific-
ally expressed on rat DC. DC were cultured with LPS (100
ng/ml, Sigma-Aldrich), with or without the caspase-1 in-
hibitor Ac-YVAD-cmk (8 μM, Cayman Chemical) for 48 h.
Then DC were collected, and CD80, CD86, MHC class II,
and IL-1β were determined by flow cytometric analysis.
Flow cytometric analysis of DC
For phenotypic analysis, DCs were washed with 0.5 %
bovine serum albumin (BSA; Sigma-Aldrich) in PBS and
stained with PE-conjugated anti-rat CD80 (BioLegend,
San Diego, CA, USA), FITC-conjugated anti-rat CD86
(BioLegend), and FITC-conjugated anti-rat MHC class II
monoclonal antibodies (eBioscience, San Die go, CA,
USA) for 30 min at 4 °C in the dark, respectively.
Preparation of lymph node mononuclear cells
Mononuclear cell (MNC) suspensions from inguinal lymph
nodes were prepared by grinding through cell strainers in
serum-free medium. Then, cells were washed three times
and resuspended to 2 × 106/ml in RPMI 1640 (HyClone)
supplemented with 1 % (v/v) penicillin-streptomycin
(Shandong Lukang Cisen) and 10 % (v/v) fetal bovine
serum (Gibco) for the following experiments.
Flow cytometric analysis of lymph node MNC
After extracellular staining for surface with PerCP-
conjugated anti-rat CD3 (eBioscience), PE-conjugated
anti-rat CD4 (BioLegend), PE-conjugated anti-rat γδ
TCR (eBioscience), and PE-conjugated anti-rat OX62
(BD Biosciences, San Jose, CA, USA), lymph node
mononuclear cells were then fixed with 2 % paraformalde-
hyde for 20 min at 4 °C and permeabilized with 0.5 % sap-
onin and stained intracellularly with FITC-conjugated
anti-rat IL-17 (eBioscience) and FITC-conjugated anti-rat
IL-1β (Abcam, San Francisco, CA, USA). Treg cells were
identified by extracellular staining with FITC-conjugated
anti-rat CD4 (eBioscience), PE-conjugated anti-rat CD25
(eBioscience), after fixation and permeabilization, PE-Cy5-
conjugated anti-mouse/rat Foxp3 antibodies (eBioscience)
was used for staining according to the protocol recom-
mended. Follicular helper T (Tfh) cells were defined by
extracellular staining with PE anti-rat-CD4 (BioLegend),
PE-Cy7 anit-rat-ICOS (eBioscience), and FITC anti-rat-
CXCR5 (Abcam). Then, samples were analyzed within 24
h with a BD FACScan (BD Biosciences) using Cell Quest
software (BD Biosciences).Cell proliferation assay
Cell viability was assessed by measuring the conversion
of the trazolium salt WST-8 to formazan according
to the manufacturer’s instructions [Cell Counting Kit-8
(CCK-8); Dojindo, Kumamoto, Japan] [17]. Briefly, MNC
suspended in 200-μl aliquots containing 4 × 105 cells
were cultured in triplicates in flat-bottomed 96-well mi-
crotitre plates (Corning, NY, USA) in the absence or
presence of R97-116 peptide (10 μg/ml). Negative con-
trols were incubated with RPMI 1640 (HyClone). After
72 h of incubation in a humidified atmosphere of 95 %
air and 5 % CO2 at 37 °C, the cells were incubated with
10 μl CCK-8 for 4 h at 37 °C. Then, the absorbance was
read at 450 nm subtracted from 630 nm on a microplate
reader and results were expressed as OD values ± SD.Cytokine assay by ELISA
Supernatants were removed after 72 h of culture, and
IL-1β (eBioscience) or IL-17 (BioLegend) concentrations
were determined by sandwich ELISA kits according to
the manufacturer’s instructions. Supernatant samples
and standard samples were added to the wells and incu-
bated for 2 h at room temperature. After washing, the
plates were incubated for 1 h with detection antibody
solution. Then, Avidin-HRP solution was added, incu-
bated at room temperature for 30 min. Plates were
followed by development with substrate solution. Finally,
OD value into each well was measured at 450 nm sub-
tracted from 570 nm using a microplate ELISA reader.
Determinations were performed in duplicate and the re-
sults were expressed as picograms per milliliter. Results
were expressed as mean OD value of samples ± SD.Detection of serum anti-R97-116 peptide IgG antibody
by ELISA
Microtitre plates (Coaster, Cambridge, MA, USA) were
coated with R97-116 peptide (5 μg/ml) at 4 °C over
night. Then, the plates were blocked with 200 μl of PBS
containing 0.05 % Tween 20 and 10 % FBS at 37 °C for
1.5 h. Serum samples (1:100 in PBS/0.05 % Tween 20)
were added to the wells and incubated for 2 h at 37 °C.
After washing, the plates were incubated for 1 h with
biotinylated rabbit anti-rat IgG (1:3000; Biosynthesis Bio-
technology, Beijing, China). Then, streptavidin-horseradish
peroxidase (1:1000; Biosynthesis Biotechnology) was added,
incubated at 37 °C for 30 min. Plates were washed with
PBS containing 0.05 % Tween 20 and followed by develop-
ment with tetramethylbenzidine (TMB) substrate (Tiangen
Biotechnology, Beijing, China). Finally, OD value into each
well was measured at 450 nm subtracted from 630 nm
using a microplate ELISA reader. Each serum was tested in
triplicate. Results were expressed as mean OD value of
samples ± SD.
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peptide IgG antibody by ELISA
The relative affinity of anti-R97-116 antibodies was
determined by ELISA using thiocyanate elution [18].
Briefly, microplates (Coaster) were coated with R97-116
peptide (5 μg/ml) and uncoated sites were blocked with
10 % FBS (Gibco). Diluted serum with a predetermined
amount of anti-R97-116 antibodies was added and incu-
bated. Then, 200 μl of appropriate quantities of potassium
thiocyanate (KSCN) were added in duplicate and incu-
bated at room temperature for 15 min, followed by bio-
tinylated rabbit anti-rat IgG and streptavidin-horseradish
peroxidase. The color was developed with TMB and
expressed as OD value at 450 nm subtracted from 630
nm. The relative affinity is expressed as affinity index,
equal to the molarity of KSCN resulting in 50 % of the ab-
sorbance obtained in the absence of KSCN.
Statistical analysis
The SPSS 17.0 computer program (SPSS Inc., Chicago,
IL, USA) was used for all calculations and statistical
evaluations. Differences between two groups were tested
by two-tailed Student t test and among three groups by
one-factor analysis of variance (ANOVA) followed by
least significant difference (LSD) test as a post hoc test.
Results were presented as means ± SD, and a level of
p < 0.05 was considered significant.
Results
Effects of caspase-1 inhibitor on the phenotype and
intracellular cytokines of DCs in vitro
To explore whether caspase-1 inhibitor could suppress
the maturation of DCs, DCs were cultured with or with-
out Ac-YVAD-cmk, and the expression of CD80, CD86,
and MHC class II on DCs were analyzed by flow cytom-
etry. The phenotypic analysis of spleen DCs showed that
the expression of CD86 and MHC class II were inhibited
by caspase-1 inhibitor (p < 0.05, respectively) in vitro.
Furthermore, the intracellular IL-1β from spleen DCs
cultured with or without Ac-YVAD-cmk in vitro was de-
tected by flow cytometry. The results showed that IL-1β
production was decreased by caspase-1 inhibitor in vitro
(Fig. 1a). The phenotypic analysis of bone marrow DCs
showed that the expression of CD80 and CD86 were
inhibited by caspase-1 inhibitor, and IL-1β production
was also decreased (Fig. 1b).
Caspase-1 inhibitor suppresses the development of EAMG
and regulates the phenotype of DC in EAMG
To address the role of caspase-1 inhibitor in Lewis rats
with ongoing EAMG, the EAMG rats were injected i.p.
with caspase-1 inhibitor Ac-YVAD-cmk every second
day from day 13 after the first immunization. The rats in
Ac-YVAD-cmk treatment group exhibited lower clinicalscores when compared with rats in EAMG group. On
the day of the experiment termination, the clinical
scores of the rats in Ac-YVAD-cmk treatment group av-
eraged 0.54 ± 0.29, while the EAMG group developed
more severe symptom, and the clinical scores averaged
1.37 ± 0.34 (p < 0.01) (Fig. 2a). Serum was collected on
day 43 p.i. to determine anti-R97-116 peptide IgG pro-
duction by ELISA. There was no difference for the levels
of anti-R97-116 IgG between Ac-YVAD-cmk and EAMG
groups. However, the affinity in Ac-YVAD-cmk group
was lower than that in EAMG group (Fig. 2b). Further,
the percentages of CD86 and MHC class II positive cells
among OX62+DC were significantly (p < 0.05) decreased
in rats treated with Ac-YVAD-cmk compared to that in
EAMG rats in vivo (Fig. 2c).
Effects of exogenous IL-1β on the caspase-1 inhibitor
in EAMG
To investigate the mechanism of caspase-1 inhibitor on
EAMG, the EAMG rats were injected i.p. with caspase-1
inhibitor Ac-YVAD-cmk and IL-1β. The rats in Ac-
YVAD-cmk with IL-1β group exhibited higher clinical
scores when compared with rats in Ac-YVAD-cmk treat-
ment group (p < 0.05, from day 34 to day 43 p.i.). More-
over, the clinical symptoms between Ac-YVAD-cmk with
IL-1β group and EAMG group did not differ signifi-
cantly (Fig. 3a). The results of IL-1β on humoral im-
mune responses showed that the level of anti-R97-116
IgG in rats treated with Ac-YVAD-cmk with IL-1β was
dramatically increased compared with the other two
groups (p < 0.01 for both comparisons). Lower affinity
indexes of anti-R97-116 peptide IgG in two treated
groups was observed compared with that in EAMG rats
(p < 0.01 for both comparisons). Together, the above
results suggested that caspase-1 inhibitor decreased
the affinity of anti-R97-116 peptide IgG in EAMG rats
and exogenous IL-1β increased the production of anti-
R97-116 antibody without improving the affinity
(Fig. 3b). Furthermore, there was no difference for the
levels of anti-R97-116 IgG1, IgG2a, and IgG2b between
EAMG group and Ac-YVAD-cmk group. The level of
anti-R97-116 IgG1 and G2a in rats treated with Ac-
YVAD-cmk with IL-1β was dramatically increased com-
pared with the other two groups (p < 0.05, p < 0.001,
respectively) (Fig. 3c).
Caspase-1 inhibitor attenuates EAMG via suppressing DC
IL-1β, CD4+ T and γδ T cells IL-17 pathways
To further investigate the mechanism underlying the ef-
fects of caspase-1 inhibitor on EAMG, we detected the
intracellular IL-1β, IL-17 production from lymph node
by flow cytometry. As shown in Fig. 4a, the percentage
of IL-1β positive cells among OX62+ DC was reduced in
rats treated with Ac-YVAD-cmk when compared with
Fig. 1 Effects of caspase-1 inhibitor on the phenotype and IL-1β of DCs in vitro. DC from Lewis rats were stimulated with LPS (100 ng/ml) and
cultured with the caspase-1 inhibitor Ac-YVAD-cmk (8 μM) for 48 h. Expression of CD80, CD86, MHC class II, and IL-1β from spleen DC (a) and
bone marrow DC (b) were assessed by FACS. Data are expressed as mean ± SD of n = 3 rats/group representative of three independent
experiments (*p < 0.05)
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by IL-1β but not statistically significant (p = 0.2). There
was no difference between EAMG group and Ac-YVAD-
cmk with IL-1β group. Secondly, we detected theintracellular IL-17 production by flow cytometry. The
percentage of CD4+ IL-17+ cells was reduced in rats
treated with Ac-YVAD-cmk when compared with that in
EAMG rats (p < 0.05), which was partly reversed by
Fig. 2 Caspase-1 inhibitor ameliorated EAMG severity and decreased the expression of CD86 and MHC class II among OX62+DC in EAMG rats.
The rats in Ac-YVAD-cmk treatment group exhibited lower clinical scores when compared with rats in EAMG group (**p < 0.01) (a). The serum
was obtained on day 43 p.i. and anti-R97-116 IgG titer and affinity were determined (b). MNCs were isolated from the lymph nodes of rats in
EAMG and Ac-YVAD-cmk groups. Expression of CD86 and MHC class II among OX62+DC were decreased in rats treated with Ac-YVAD-cmk
compared to that in EAMG rats in vivo (*p < 0.05) (c)
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(Fig. 4b). γδ T cells have been shown to be an important
source of IL-17 in the course of autoimmune diseases
and have a pathogenic role during the development of
diseases. In our study, there were no differences among
the three groups in terms of the numbers of γδ T cells
in MNC from lymph nodes (Fig. 4c). However, the per-
centage of IL-17-expressing γδ T cells was reduced in
rats treated with Ac-YVAD-cmk when compared with
that in EAMG rats (p < 0.05), and there were no statis-
tical difference between two treatment groups (Fig. 4d).
We next examined the levels of IL-1β and IL-17 inculture supernatants of lymphocytes stimulated with
R97-116 peptide. The production of IL-1β in the culture
supernatants of Ac-YVAD-cmk treated group was reduced
when compared with that in EAMG group (p < 0.05). The
production of IL-1β in the culture supernatants in rats
treated with Ac-YVAD-cmk and IL-1β was increased
when compared with that in Ac-YVAD-cmk rats, but this
difference did not reach to a statistically significant value
(p = 0.24). There was no difference between EAMG group
and Ac-YVAD-cmk with IL-1β group (Fig. 4e). There were
no differences for the levels of IL-17 among the three
groups (Fig. 4f).
Fig. 3 Administration of exogenous IL-1β in vivo aggravated the severity of EAMG rats treated with Ac-YVAD-cmk. The rats treated with Ac-YVAD-cmk
showed lower clinical scores from day 30 to 43 p.i. compared with rats in Ac-YVAD-cmk with IL-1β group (#p < 0.05) and EAMG group (*p < 0.05)
(a). Anti-R97-116 peptide IgG titers and the affinity index of anti-R97-116 peptide IgG were determined by ELISA, and results were determined by
OD values at 450 nm subtracted from 630 nm (b). Anti-R97-116 peptide IgG1, IgG2a, and IgG2b titers were determined by ELISA, and results were
determined by OD values at 450 nm subtracted from 630 nm (c). Serum was obtained on day 43 p.i. All results are expressed as means ± SD (n = 6 in
each group) (*p < 0.05, **p < 0.01, and ***p < 0.001)
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and CD4+CD25+Foxp3+ T, CD4+CXCR5+ICOS+ T cell subset
differentiation
We examined whether the effects of caspase-1 inhibitor
was correlated with Treg cells in EAMG rats. The results
showed that there was no difference for the percentage of
CD4+CD25+Foxp3+ T cells among three groups, respect-
ively, suggesting that caspase-1 inhibitor induced immune
suppression rather than by CD25+Foxp3+ T regular cells in
the present study (Fig. 5a). Follicular helper T cells are able
to provide essential help to the antigen-specific B cells
within the secondary lymphoid organ. The percentage of
CD4+CXCR5+ICOS+ Tfh cells in rats treated with Ac-
YVAD-cmk decreased compared with that in EAMG rats
(p < 0.01). The percentage of CD4+CXCR5+ICOS+ Tfh
cells in rats treated with Ac-YVAD-cmk with IL-1β exhib-
ited a decreased trend but did not reach the statistically
significant value (p = 0.07) compared with that in EAMG
group. These data suggested that caspase-1 inhibitor may
alter humoral immune responses in EAMG associated
with influencing Tfh population (Fig. 5b). Lymphocyte
proliferation was measured after 72 h of culture in the ab-
sence or presence of R97-116 peptide by using the CCK-8
assay. In the absence or presence of R97-116 antigen,
lymphocyte proliferation in Ac-YVAD-cmk group wasdecreased compared with that in EAMG group (p < 0.01
and p < 0.05, respectively). Meanwhile, we did not find stat-
istical difference between two treatment groups (Fig. 5c).
Discussion
The new finding of this study is that caspase-1 inhibitor
treatment ameliorated EAMG severity. We found that
caspase-1 inhibitor suppressed the expression of co-
stimulatory molecules CD80, CD86, and MHC class II on
the surface of the DCs and the expression of intracellular
IL-1β of the DCs. Inhibition of caspase-1 suppressed IL-17
expression by γδ T cells and CD4+ T cells. Furthermore, we
demonstrated that caspase-1 inhibitor suppressed lympho-
cyte proliferation, decreased the number of Tfh cell, and
the affinity of anti-R97-116 IgG in EAMG rats. The present
study provides convincing evidence that caspase-1 inhibitor
ameliorates EAMG by innate DC IL-1-IL-17 pathway.
Dendritic cells (DC) are professional antigen-presenting
cells (APC), playing a major role in inducing adaptive
immune responses and maintaining immunological toler-
ance. DC is the critical link between innate and adaptive
immunity, by means of cellular interactions and secretion
of pro-inflammatory and immunoregulatory cytokines [19].
The functional activities of DC depend on their state of ac-
tivation and maturation. Mature DCs (mDC) can efficiently
Fig. 4 (See legend on next page.)
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Fig. 4 Potential mechanism underlying the effects of caspase-1 inhibitor on EAMG. MNCs were isolated from the lymph nodes of rats in respective
groups. Expression of IL-1β positive cells among OX62+ DC was assessed by FACS as indicated (a). Cells were stained for surface γδ TCR and CD4 as
well as intracellular IL-17 and analyzed by flow cytometry. Results are mean percentages of CD4+IL-17+ cells (b), γδ T cells (c), and IL-17+ γδ T cells
(d). On day 43 p.i., lymphocytes were purified from the lymph nodes and co-cultured with R97-116 peptide. Supernatants were harvested after 72 h of
co-culture. The levels of IL-1β (e) and IL-17 (f) were determined by ELISA. Data are expressed as means ± SD (n = 6 in each group) (*p < 0.05)
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whereas immature DCs (imDC) can lead to immune toler-
ance or delay the immune response by inducing T cell
anergy and decreasing the T cell proliferation. Typically,
mature DCs are associated with increased expression of co-
stimulatory molecules CD86 and MHC class II [20, 21].Fig. 5 Caspase-1 inhibitor suppressed Tfh cells and lymphocyte proliferatio
from the lymph nodes of rats in three groups. CD4+CD25+Foxp3+ T cells (a
indicated. Proliferation response of lymphocytes derived from three groups
by using CCK-8 and OD values at 450 nm subtracted from 630 nm (c). The
and **p < 0.01)Stimulation of DCs induced high concentrations of IL-1β
[15], and the release of IL-1β could be in the form of auto-
crine role in DCs itself to promote the maturity of the DCs
[22]. Furthermore, DC-based vaccines matured with a gold
standard maturation cocktail consisting of IL-1β [23]. TiO2
and SiO2 nanoparticles could activate caspase-1 and led ton but did not influence Treg cells in EAMG rats. MNCs were isolated
) and CD4+CXCR5+ICOS+ T cells (b) were assessed by FACS as
were studied on day 43 p.i.. Lymphocyte proliferation was measured
results are expressed as means ± SD (n = 6 in each group) (*p < 0.05
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via the secretion of IL-1β [24]. Consistent with these find-
ings, we found that inhibition of caspase-1 decreased the
expression of CD80, CD86, and MHC class II of DC, sup-
pressed IL-1β production by DC, and decreased the pro-
duction of IL-1β in culture MNC supernatants.
In the present study, caspase-1 inhibitor suppressed
lymphocyte proliferation in EAMG. Decreased prolifera-
tion of R97-116 specific T lymphocytes may contribute
to the clinical improvement and immune tolerance in-
duction in EAMG.
Th17 cells, CD4+ T cells that secrete IL-17, are patho-
genic in autoimmune diseases, and their differentiation and
expansion are driven by the cytokines IL-6 and TGF-β [25–
27]. Furthermore, it has recently been reported that IL-1
signaling is critical for Th17 cell differentiation [28]. γδ T
cells, an unconventional T cell subset which bridges the in-
nate and adaptive immune responses, have been shown to
play a pathogenic role early in inflammatory response. γδ T
cells can secrete IL-17 during infection, which is independ-
ent of IL-6, an essential cytokine for driving the develop-
ment of Th17 cells [29]. However, recent studies have
shown that early IL-17 from γδ T cells may promote the
induction or activation of Th17 cells, which requires for IL-
1β. The mechanism that innate IL-17 from γδ T cells pro-
motes the induction or activation of Th17 cells might be
due to both directly by interacting with IL-17R on CD4+ T
cell and indirectly by enhancing the production of cytokines
and chemokines from DCs to promote the development of
Th17 cells. First, IL-17 and IL-21 produced by γδ T cells
can promote IL-17 production by Th17 cells [30]. Second,
the production of IL-23, IL-1β, IL-6, TGF-β, CCL2, and
CXCL10 from DCs promote the expansion and recruit-
ment of Th17 cells. This is consistent with our conclusion
that inhibition of caspase-1 suppressed intracellular IL-17
production by γδ T cells and CD4+ T cells, although it did
not decrease IL-17 level in culture MNC supernatants.
Flow cytometry analysis shows the instant intracellular pro-
duction of IL-17 by CD4+ T cells and γδ T cells, but ELISA
detects the accumulated levels of IL-17 released by MNCs
to the supernatants, which is affected by various factors,
like culture time and the volume of culture medium. In
addition, a range of immune cell types have all been shown
to secrete IL-17 in vivo, and the experimental result in vitro
could not fully reflect complex environment in vivo. So, for
ELISA analysis, the differences between groups may be di-
minished by these factors. However, we found that adminis-
tration of IL-1β in vivo could not reverse the suppressive
effects of caspase-1 inhibitor on Th17 cells. Consistent with
our findings, previous studies have shown that IL-1β as a
single stimulus could not induce IL-17 production, which
may require assistance of other cytokines like IL-23 for
further study [31, 32]. The more severe disease in Ac-
YVAD-cmk with IL-1β group may due to the directlypathogenic role of IL-1β itself compared with the Ac-
YVAD-cmk group, which may be independent of IL-17
pathway. In our study, the level of anti-R97-116 IgG in Ac-
YVAD-cmk with IL-1β group was dramatically increased
compared with that in Ac-YVAD-cmk group, and there
were no differences for the affinity indexes of anti-R97-116
peptide IgG in two treated groups. Hence, IL-1β was able
to override the effect of caspase-1 inhibitor on clinical se-
verity. Compared with wild-type mice, IL-1β−/− mice sup-
pressed the development of clinical EAMG, by means of
reducing levels of serum anti-AChR antibodies and Th1
(IFN-γ, IL-2) and Th2 (IL-4) cytokine responses [33].
The role of IL-1β in antibody production has been re-
ported. IL-1 could increase serum IgE and IgG1 levels
when LPS is used as an adjuvant [34]. In an earlier study,
carp IL-1β enhanced the humoral antibody response, in-
creasing a major fish pathogen antibody [35]. In the
present study, we found that the caspase-1 inhibitor has
no effect on anti-R97-116 peptide IgG production, and
the level of IgG, IgG1, and IgG2a in the group treated
with IL-1β was increased, which was associated with the
role for IL-1β in antibody production.
Antibody affinity maturation occurs within the special-
ized microenvironment of germinal centers (GC). Tfh cells,
a recently defined CD4+ T cell subset characterized by the
expression of the chemokine receptor CXCR5 and the
transcriptional factor Bcl-6, provide a help for B cells to en-
hance antibody responses and undergo antibody affinity
maturation in the germinal center [36–39]. Tfh cell differ-
entiation could be divided into two stages: priming and
maintenance stages. At the early differentiation of Tfh, DC
priming is sufficient to induce Bcl-6 expression and initial
Tfh cell differentiation [40]. The inducible regulatory T
cells and the tolerogenic DC could inhibit Tfh cells [41]. In
our study, caspase-1 inhibitor decreased the number of
Tfh cells by inhibiting DC maturation, which may further
decrease the affinity of anti-R97-116 peptide IgG.
Conclusion
Our data suggested that caspase-1 inhibitor can inhibit DC
maturation and IL-1β production from DC, resulting in the
lower number of Tfh and decreased IL-17 production by
γδ T cells and CD4+ T cells, decreasing the affinity of anti-
R97-116 peptide IgG, thereby suppressing EAMG progres-
sion. Administration of exogenous IL-1β in vivo could not
reverse the suppressive effects of caspase-1 inhibitor. These
data suggested that caspase-1 inhibitor has greater poten-
tial for the treatment of EAMG and even human MG.
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